Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...